153 related articles for article (PubMed ID: 37469042)
21. Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.
Schmäche T; Fohgrub J; Klimova A; Laaber K; Drukewitz S; Merboth F; Hennig A; Seidlitz T; Herbst F; Baenke F; Ada AM; Groß T; Wenzel C; Ball CR; Praetorius C; Schmidt T; Ringelband-Schilling B; Koschny R; Stenzinger A; Roeder I; Jaeger D; Zeissig S; Welsch T; Aust D; Glimm H; Folprecht G; Weitz J; Haag GM; Stange DE
Mol Cancer; 2024 Jan; 23(1):10. PubMed ID: 38200602
[TBL] [Abstract][Full Text] [Related]
22. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
[TBL] [Abstract][Full Text] [Related]
23. Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer.
Watanabe S; Yogo A; Otsubo T; Umehara H; Oishi J; Kodo T; Masui T; Takaishi S; Seno H; Uemoto S; Hatano E
BMC Cancer; 2022 May; 22(1):489. PubMed ID: 35505283
[TBL] [Abstract][Full Text] [Related]
24. Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
Kim SY; Kim SM; Lim S; Lee JY; Choi SJ; Yang SD; Yun MR; Kim CG; Gu SR; Park C; Park AY; Lim SM; Heo SG; Kim H; Cho BC
Clin Cancer Res; 2021 Aug; 27(15):4397-4409. PubMed ID: 34083237
[TBL] [Abstract][Full Text] [Related]
25. The dietary flavone luteolin epigenetically activates the Nrf2 pathway and blocks cell transformation in human colorectal cancer HCT116 cells.
Zuo Q; Wu R; Xiao X; Yang C; Yang Y; Wang C; Lin L; Kong AN
J Cell Biochem; 2018 Nov; 119(11):9573-9582. PubMed ID: 30129150
[TBL] [Abstract][Full Text] [Related]
26. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.
Vlachogiannis G; Hedayat S; Vatsiou A; Jamin Y; Fernández-Mateos J; Khan K; Lampis A; Eason K; Huntingford I; Burke R; Rata M; Koh DM; Tunariu N; Collins D; Hulkki-Wilson S; Ragulan C; Spiteri I; Moorcraft SY; Chau I; Rao S; Watkins D; Fotiadis N; Bali M; Darvish-Damavandi M; Lote H; Eltahir Z; Smyth EC; Begum R; Clarke PA; Hahne JC; Dowsett M; de Bono J; Workman P; Sadanandam A; Fassan M; Sansom OJ; Eccles S; Starling N; Braconi C; Sottoriva A; Robinson SP; Cunningham D; Valeri N
Science; 2018 Feb; 359(6378):920-926. PubMed ID: 29472484
[TBL] [Abstract][Full Text] [Related]
27. "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction".
Papaccio F; García-Mico B; Gimeno-Valiente F; Cabeza-Segura M; Gambardella V; Gutiérrez-Bravo MF; Alfaro-Cervelló C; Martinez-Ciarpaglini C; Rentero-Garrido P; Zúñiga-Trejos S; Carbonell-Asins JA; Fleitas T; Roselló S; Huerta M; Sánchez Del Pino MM; Sabater L; Roda D; Tarazona N; Cervantes A; Castillo J
J Exp Clin Cancer Res; 2023 Jan; 42(1):8. PubMed ID: 36604765
[TBL] [Abstract][Full Text] [Related]
28. Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer.
He X; Jiang Y; Zhang L; Li Y; Hu X; Hua G; Cai S; Mo S; Peng J
Front Bioeng Biotechnol; 2023; 11():1190637. PubMed ID: 37284236
[No Abstract] [Full Text] [Related]
29. Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin.
Saeki S; Kumegawa K; Takahashi Y; Yang L; Osako T; Yasen M; Otsuji K; Miyata K; Yamakawa K; Suzuka J; Sakimoto Y; Ozaki Y; Takano T; Sano T; Noda T; Ohno S; Yao R; Ueno T; Maruyama R
Breast Cancer Res; 2023 Feb; 25(1):21. PubMed ID: 36810117
[TBL] [Abstract][Full Text] [Related]
30. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Chakrabarti M; Ray SK
Apoptosis; 2016 Mar; 21(3):312-28. PubMed ID: 26573275
[TBL] [Abstract][Full Text] [Related]
31. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids.
Koh V; Chakrabarti J; Torvund M; Steele N; Hawkins JA; Ito Y; Wang J; Helmrath MA; Merchant JL; Ahmed SA; Shabbir A; Yan So JB; Yong WP; Zavros Y
Cancer Lett; 2021 Oct; 518():59-71. PubMed ID: 34126195
[TBL] [Abstract][Full Text] [Related]
32. Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment.
Wang Y; Wang Q; Feng W; Yuan Q; Qi X; Chen S; Yao P; Dai Q; Xia P; Zhang D; Sun F
Drug Deliv; 2021 Dec; 28(1):1695-1708. PubMed ID: 34402706
[TBL] [Abstract][Full Text] [Related]
33. Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients.
Geevimaan K; Guo JY; Shen CN; Jiang JK; Fann CSJ; Hwang MJ; Shui JW; Lin HT; Wang MJ; Shih HC; Li AF; Chang SC; Yang SH; Chen JY
Front Oncol; 2022; 12():883437. PubMed ID: 35719949
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract][Full Text] [Related]
35. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
Lu J; Li G; He K; Jiang W; Xu C; Li Z; Wang H; Wang W; Wang H; Teng X; Teng L
J Transl Med; 2015 Feb; 13():42. PubMed ID: 25638174
[TBL] [Abstract][Full Text] [Related]
36. Metabolism of parathyroid organoids.
Sekhar KR; Codreanu SG; Williams OC; Rathmell JC; Rathmell WK; McLean JA; Sherrod SD; Baregamian N
Front Endocrinol (Lausanne); 2023; 14():1223312. PubMed ID: 37492197
[TBL] [Abstract][Full Text] [Related]
37. Lactate promotes the growth of patient-derived organoids from hepatopancreatobiliary cancers via ENO1/HIF1α pathway and does not affect their drug sensitivities.
Wang Z; Yu Y; Wu P; Ye Q; Guo Y; Zhang X; Xi L; Li Q; Jin Y; Zhou D; Luo Y; Peng S; Li J
Cell Death Discov; 2022 Apr; 8(1):214. PubMed ID: 35443744
[TBL] [Abstract][Full Text] [Related]
38. CRISPR/Cas9 Screen in Gastric Cancer Patient-Derived Organoids Reveals KDM1A-NDRG1 Axis as a Targetable Vulnerability.
Mircetic J; Camgöz A; Abohawya M; Ding L; Dietzel J; Tobar SG; Paszkowski-Rogacz M; Seidlitz T; Schmäche T; Mehnert MC; Sidorova O; Weitz J; Buchholz F; Stange DE
Small Methods; 2023 Jun; 7(6):e2201605. PubMed ID: 36908010
[TBL] [Abstract][Full Text] [Related]
39. Combination of metformin and luteolin synergistically protects carbon tetrachloride-induced hepatotoxicity: Mechanism involves antioxidant, anti-inflammatory, antiapoptotic, and Nrf2/HO-1 signaling pathway.
Yan Y; Jun C; Lu Y; Jiangmei S
Biofactors; 2019 Jul; 45(4):598-606. PubMed ID: 31336028
[TBL] [Abstract][Full Text] [Related]
40. Patient-derived Tumour Organoids: A Bridge between Cancer Biology and Personalised Therapy.
Wu W; Li X; Yu S
Acta Biomater; 2022 Jul; 146():23-36. PubMed ID: 35533925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
